NCT04774055

Brief Summary

Brain injury remains the leading cause of death in comatose patients resuscitated from OHCA. One of the most challenging aspects in the treatment of a post-cardiac arrest patient is the assessment of the extent of brain damage. Reliable, clinical measures of ongoing brain injury have potential to guide individualized treatment and potentially improve outcomes. Persistent candidate measures to fill this role is combined cerebral metabolism monitoring assessed by jugular bulb microdialysis (JBM) and positron emission tomography (PET) of 18-Fluor deoxyglucose (\[F-18\]-FDG). This multimodal neuromonitoring is cutting-edge technology used in a clinical setting

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Feb 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 23, 2021

Completed
2 days until next milestone

Study Start

First participant enrolled

February 25, 2021

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 26, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2023

Completed
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2023

Completed
Last Updated

April 20, 2022

Status Verified

April 1, 2022

Enrollment Period

2 years

First QC Date

February 23, 2021

Last Update Submit

April 19, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Overall CMRglc

    Cerebral metabolic rate of glucose (CMRglc)

    Day 0 after cardiac arrest

  • Overall CMRglc

    Cerebral metabolic rate of glucose (CMRglc)

    Day 3 after cardiac arrest

Secondary Outcomes (2)

  • Jugular bulb microdialysis (JBM) LP ratio

    Day 0 after cardiac arrest

  • JBM LP ratio

    Day 3 after cardiac arrest

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Comatose patients after OHCA admitted to the hospital with sustained return of spontaneous circulation

You may qualify if:

  • Out-of-hospital cardiac arrest (OHCA) of presumed cardiac cause
  • Sustained return of spontaneous circulation (ROSC), defined as ROSC when chest compressions have not been required for 20 consecutive minutes and signs of circulation persist
  • Unconsciousness (Glasgow Coma Scale (GCS) score of less than 8) after sustained ROSC
  • Target temperature management (TTM) is indicated.

You may not qualify if:

  • Conscious patient (GCS score of at least 8)
  • In-hospital cardiac arrest (IHCA)
  • OHCA of presumed non-cardiac cause, such as after trauma, dissection/rupture of major artery or arrest caused by hypoxia (i.e., drowning, hanging, etc.)
  • Known bleeding diathesis (medically induced coagulopathy does not exclude patient)
  • Suspected or confirmed acute intracranial bleeding
  • Suspected or confirmed acute ischemic stroke
  • Unwitnessed asystole
  • Known limitations in therapy and do-not-resuscitate order

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Odense University Hospital

Odense, Fyn, 5000, Denmark

RECRUITING

MeSH Terms

Conditions

Heart ArrestBrain Injuries

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and Injuries

Study Officials

  • Simon Mølstrøm, MD

    Odense University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Simon Mølstrøm, MD

CONTACT

Palle Toft, Prof

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant physician

Study Record Dates

First Submitted

February 23, 2021

First Posted

February 26, 2021

Study Start

February 25, 2021

Primary Completion

March 1, 2023

Study Completion

December 1, 2023

Last Updated

April 20, 2022

Record last verified: 2022-04

Locations